Navigation Links
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Date:10/10/2008

tipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs.

Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including quetiapine. Patients with a pre-existing low white blood cell (WBC) count or a history of drug induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/mm.(3)

Tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs admin
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company ... value and difficult to manufacture proteins, today announced the ... of its common stock at a price to the ... offered, 2,610,000 are being offered by Pfenex and the ... Pfenex will not receive any proceeds from the shares ...
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... April 23, 2015 WuXi PharmaTech (Cayman) Inc. ... and technology platform company serving the pharmaceutical, biotechnology and ... and the United States ... for the first quarter of 2015 after the New ... (which will be Thursday morning, May 14, 2015 Shanghai ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... Oct. ... , ... 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s future ... 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies will ...
... In its newly published Lockton Market Update ... that the markets are in a relative state of calm ... The online update includes snapshots of more than two dozen ... officers and other executives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090415/CG99351LOGO ...
... PRINCETON, N.J., Sept. 30 DOR BioPharma, Inc. (OTC Bulletin ... has completed a corporate name change from DOR BioPharma, Inc. ... of the name change, the Company,s shares of common stock ... as of today. , "We are pleased to ...
Cached Biology Technology:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Commercial Insurance Buyers Benefit From Ample Capacity 2Commercial Insurance Buyers Benefit From Ample Capacity 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... wastewater fuel cell, researchers have coaxed common bacteria to ... Logan and colleagues at Penn State University had already ... using starter material that could theoretically be sourced from ... microbes to generate hydrogen. By tweaking their design, ...
... 2007) A major study that will provide a new ... conducted by the La Jolla Institute for Allergy & ... The five-year study, funded by the National Institute of ... Institutes of Health, could lead to revolutionary new approaches ...
... Nov. 12, 2007 Visually unsettling and intellectually provocative, John ... Chervinsky, a photographer with a strong background in physics, ... Experiment in Perspective at the University of Houston at 7 ... Hoffman Hall. The event is free and open to ...
Cached Biology News:Microbes churn out hydrogen at record rate 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4Art meets science: Engineer discusses his photographs in free UH lecture 2